Please Wait
Applying Filters...
menu
    • menu
    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-24

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Gentec Pharmaceutical Group is focused on manufacturing & developing APIs/HPAPIs, Advanced Intermediates & Fine Chemicals.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-17

    Virtual Booth

    Contact Supplier

    Menu

    Amifampridine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 35,526Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Catalyst Sub-Licensee DyDo Pharma Launches FIRDAPSE® In Japan
    Catalyst Sub-Licensee DyDo Pharma Launches FIRDAPSE® In Japan

    21 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/21/3012650/13009/en/Catalyst-Pharmaceuticals-Announces-Sub-Licensee-DyDo-Pharma-Launched-FIRDAPSE-in-Japan.html

    GLOBENEWSWIRE
    21 Jan 2025
    Share Share
    Catalyst's Teva settlement postpones arrival of Firdapse generic
    Catalyst's Teva settlement postpones arrival of Firdapse generic

    09 Jan 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/catalyst-settles-teva-help-stave-firdapse-generic-until-2035

    FIERCE PHARMA
    09 Jan 2025
    Share Share
    Catalyst’s Sub-Licensee DyDo Gets Approval for FIRDAPSE in Japan
    Catalyst’s Sub-Licensee DyDo Gets Approval for FIRDAPSE in Japan

    24 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/24/2951972/13009/en/Catalyst-Pharmaceuticals-Announces-Sub-Licensee-DyDo-Pharma-Received-Approval-to-Commercialize-FIRDAPSE-in-Japan.html

    GLOBENEWSWIRE
    24 Sep 2024
    Share Share
    Catalyst Gets Higher FIRDAPSE® Maximum Dose Approval From FDA
    Catalyst Gets Higher FIRDAPSE® Maximum Dose Approval From FDA

    31 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/30/2891040/13009/en/Catalyst-Pharmaceuticals-Receives-U-S-FDA-Approval-For-Increased-Maximum-Daily-Dose-For-FIRDAPSE.html

    GLOBENEWSWIRE
    31 May 2024
    Share Share
    Catalyst to Participate in the 2024 Cantor Virtual MDS
    Catalyst to Participate in the 2024 Cantor Virtual MDS

    27 Mar 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/03/27/2853130/13009/en/Catalyst-Pharmaceuticals-to-Participate-in-the-2024-Cantor-Virtual-Muscular-Dystrophy-Symposium.html

    GLOBENEWSWIRE
    27 Mar 2024
    Share Share
    Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE®
    Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE®

    02 Nov 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/11/02/2772557/13009/en/Catalyst-Pharmaceuticals-Receives-Two-New-U-S-Patent-Allowances-For-FIRDAPSE.html

    GLOBENEWSWIRE
    02 Nov 2023
    Share Share